Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, 624 North Broadway, Baltimore, MD 21205, USA; Johns Hopkins Center for Mental Health and Addiction Policy, 624 North Broadway, Baltimore, MD 21205, USA.
Johns Hopkins Center for Mental Health and Addiction Policy, 624 North Broadway, Baltimore, MD 21205, USA; Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, 624 North Broadway, Baltimore, MD 21205, USA.
Drug Alcohol Depend. 2021 Sep 1;226:108881. doi: 10.1016/j.drugalcdep.2021.108881. Epub 2021 Jun 26.
Four million individuals in the U.S. criminal-legal system are supervised in the community under probation or parole. Sentences to community supervision often mandate participation in substance use treatment. Yet evidence-based treatment with medication (i.e., methadone, buprenorphine, or naltrexone) is rarely offered to people under community supervision with opioid use disorder (OUD). This qualitative study explores the structural and organizational factors shaping OUD medication treatment use in community supervision.
We conducted in-depth interviews with 31 community supervision professionals. Thematic analysis characterized interview participants' perceptions of the key factors shaping use of OUD medications in community supervision.
Findings indicate that authorities making decisions about OUD treatment include community supervision agencies, treatment providers, judges and courts, and jails and prisons. Agencies with more rehabilitative cultural orientations are more forgiving of relapse and supportive of OUD medications. Punishment/enforcement orientations align with an emphasis on surveillance and drug testing, which can inhibit medication treatment and interrupt continuity of care. Community supervision agencies generally reported deference to the recommendations of substance use treatment providers regarding the details of treatment, including the use of medication. Given that most treatment providers do not offer OUD medication, community supervision agencies must develop a sophisticated understanding of the various services offered by local treatment providers to tailor referrals accordingly, a responsibility for which they may be inadequately trained.
Efforts to improve engagement with medication treatment in U.S. community supervision settings could have a significant impact on reincarceration, morbidity, and mortality among individuals with OUD under supervision.
美国刑事司法系统中有 400 万人在社区中受到缓刑或假释的监管。对社区监督的判决通常要求参与药物使用治疗。然而,对于患有阿片类药物使用障碍(OUD)的受社区监督的人,很少提供基于证据的药物治疗(即美沙酮、丁丙诺啡或纳曲酮)。这项定性研究探讨了影响 OUD 药物治疗在社区监督中使用的结构和组织因素。
我们对 31 名社区监督专业人员进行了深入访谈。主题分析描述了访谈参与者对影响社区监督中 OUD 药物使用的关键因素的看法。
研究结果表明,对 OUD 治疗做出决策的权威机构包括社区监督机构、治疗提供者、法官和法院以及监狱。具有更多康复文化取向的机构对复发更为宽容,并支持 OUD 药物治疗。惩罚/执法取向与强调监督和药物测试一致,这可能会抑制药物治疗并中断护理的连续性。社区监督机构通常报告尊重药物使用治疗提供者关于治疗细节的建议,包括药物的使用。鉴于大多数治疗提供者不提供 OUD 药物治疗,社区监督机构必须深入了解当地治疗提供者提供的各种服务,以便相应地调整转介,他们可能对此缺乏足够的培训。
在美国社区监督环境中努力改善对药物治疗的参与度可能会对监督下患有 OUD 的个人的再监禁、发病率和死亡率产生重大影响。